Search

Your search keyword '"Lindemann, Hans W."' showing total 4 results
Start Over Author "Lindemann, Hans W."
4 results on '"Lindemann, Hans W."'

1. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

Author

Fabarius, Alice, Kalmanti, Lida, Dietz, Christian T., Lauseker, Michael, Rinaldetti, Sébastien, Haferlach, Claudia, Göhring, Gudrun, Schlegelberger, Brigitte, Jotterand, Martine, Hanfstein, Benjamin, Seifarth, Wolfgang, Hänel, Mathias, Köhne, Claus-Henning, Lindemann, Hans W., Berdel, Wolfgang E., Staib, Peter, Müller, Martin C., Proetel, Ulrike, Balleisen, Leopold, Goebeler, Maria-Elisabeth, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Burchert, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Brümmendorf, Tim H., Edinger, Matthias, Hofmann, Wolf-Karsten, Pfirrmann, Markus, Hasford, Joerg, Krause, Stefan, Hochhaus, Andreas, Saußele, Susanne, Hehlmann, Rüdiger, and for the SAKK and the German CML Study Group

Published
2015
Full Text
View/download PDF

2. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Author

Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, and Weisel, Katja

Abstract

The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st–3rd relapse of multiple myeloma (MM) to a transplant arm (n= 139) consisting of 3 Rd (lenalidomide 25 mg, day 1–21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n= 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65–1.16; p= 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52–1.28; p= 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p= 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted.

Published
2021
Full Text
View/download PDF

3. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

Author

Baertsch, Marc-Andrea, primary, Schlenzka, Jana, additional, Lisenko, Katharina, additional, Krzykalla, Julia, additional, Becker, Natalia, additional, Weisel, Katja, additional, Noppeney, Richard, additional, Martin, Hans, additional, Lindemann, Hans W., additional, Haenel, Mathias, additional, Nogai, Axel, additional, Scheid, Christof, additional, Salwender, Hans, additional, Fenk, Roland, additional, Graeven, Ullrich, additional, Reimer, Peter, additional, Schmidt-Hieber, Martin, additional, Goerner, Martin, additional, Schmidt-Wolf, Ingo G. H., additional, Klein, Stefan, additional, Ho, Anthony D., additional, Goldschmidt, Hartmut, additional, and Wuchter, Patrick, additional

Published
2017
Full Text
View/download PDF

4. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Author

Baertsch, Marc-Andrea, primary, Schlenzka, Jana, additional, Mai, Elias K., additional, Merz, Maximilian, additional, Hillengaß, Jens, additional, Raab, Marc S., additional, Hose, Dirk, additional, Wuchter, Patrick, additional, Ho, Anthony D., additional, Jauch, Anna, additional, Hielscher, Thomas, additional, Kunz, Christina, additional, Luntz, Steffen, additional, Klein, Stefan, additional, Schmidt-Wolf, Ingo G. H., additional, Goerner, Martin, additional, Schmidt-Hieber, Martin, additional, Reimer, Peter, additional, Graeven, Ullrich, additional, Fenk, Roland, additional, Salwender, Hans, additional, Scheid, Christof, additional, Nogai, Axel, additional, Haenel, Mathias, additional, Lindemann, Hans W., additional, Martin, Hans, additional, Noppeney, Richard, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results